Calluna Pharma’s Post

💉🧬 𝐄𝐱𝐩𝐥𝐨𝐫𝐢𝐧𝐠 𝐭𝐡𝐞 𝐌𝐨𝐧𝐨𝐜𝐥𝐨𝐧𝐚𝐥 𝐀𝐧𝐭𝐢𝐛𝐨𝐝𝐲 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐀𝐝𝐯𝐚𝐧𝐜𝐢𝐧𝐠 𝐏𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞 𝐚𝐧𝐝 𝐓𝐚𝐫𝐠𝐞𝐭𝐞𝐝 𝐓𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 🌟💊 𝐂𝐥𝐢𝐜𝐤 𝐇𝐞𝐫𝐞, 𝐓𝐨 𝐆𝐞𝐭 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 https://lnkd.in/gKkEhPzS 💉 Key Highlights: Precision Targeting: Monoclonal antibodies (mAbs) are engineered to specifically target and bind to unique antigens or receptors on diseased cells, pathogens, or immune cells, enabling precise modulation of biological pathways, immune responses, and disease processes implicated in various medical conditions. Diverse Therapeutic Applications: Monoclonal antibody therapies encompass a wide range of therapeutic applications, including oncology, immunology, inflammatory diseases, infectious diseases, autoimmune disorders, and neurological conditions, reflecting their versatility and potential to address unmet medical needs across diverse patient populations. Personalized Treatment Approaches: Monoclonal antibody therapies are increasingly tailored to individual patient characteristics, disease subtypes, and molecular biomarkers through biomarker-driven selection, companion diagnostics, and pharmacogenomic strategies, optimizing treatment efficacy, safety, and patient outcomes. #Company AbbVie Amgen Glaxosmithkline Merck Group Novartis Roche Novartis #Type • Human Monoclonal Antibody • Humanized Monoclonal Antibody • Chimeric Monoclonal Antibody • Murine Monoclonal Antibody #Application • Cancer • Autoimmune Diseases • Others #MonoclonalAntibodies #PrecisionMedicine #TherapeuticInnovation #GlobalHealth #LinkedInPost

CAR-Ts sweep into autoimmunity Good article in Nature Biotechnology providing an overview of the biotech landscape focusing on CAR-T cells to target B cells in autoimmune disorders. - Biotechs are leveraging CAR-T cells to target B cells in multiple sclerosis and autoimmune disorders, showcasing promising early clinical findings and adding momentum to this burgeoning field. - Preliminary results from ongoing clinical studies demonstrate the potential of CAR-T therapy in eliminating autoantibodies and driving disease remission in patients with conditions such as systemic lupus erythematosus (SLE). - Strategies like transiently expressed CAR-T cells and chimeric auto-antibody receptor (CAAR) T cells are being explored to address autoimmune disorders, aiming for lasting efficacy and reduced side effects, offering a potential alternative to traditional monoclonal antibody therapies. - Off-the-shelf allogeneic CAR-T and CAR NK cells present opportunities for broader accessibility and scalability, with ongoing efforts to expand their application beyond blood cancers to autoimmune disorders, potentially transforming treatment paradigms. https://lnkd.in/eQj9uyTz #celltherapy #autoimmunity #biotech #immunology Table below: Selected CAR-T cells in Ph1 clinical trials or above for autoimmune disorders

Santa Ana Bio, Inc. Emerges With $168M Funding To Advance Precision Immunology Learn more & get our take 👇 https://lnkd.in/gsj7zh3m “Precision medicines offer the ability to target defined cell types and pathways to disrupt the pathogenic biology driving disease. By identifying pathogenic cell types and pathways, and leveraging our deep protein engineering capabilities including monoclonal, bi-specific antibodies and ADCs, we aim to expand the reach of biologics to patients across numerous inflammatory diseases.” — Peter Emtage Ph.D., CEO and Board Member at Santa Ana Bio “Each of Santa Ana’s programs builds upon clinical precedent, yet provides important differentiation from past approaches. Given the breadth of these programs and pipeline, Santa Ana clearly has optionality to advance these promising internal programs and to pursue partnerships.” — Jerel Davis, Ph.D., Managing Director at Versant Ventures and Board Chair at Santa Ana Bio “We’re thrilled to lead the Santa Ana Series B and support Peter and the team as they advance a pipeline of antibodies for autoimmune diseases. Peter is a preeminent expert in immunology and has brought together a distinguished group of scientific leaders to advance lead programs.” — Brendan Bulik-Sullivan, Ph.D., Board Member and General Partner at GV (Google Ventures) #immunology #funding #SoHCNews

Sanofi and Owkin expand AI collaboration to include drug positioning in Immunology: 🎯Building on their existing drug discovery & development collaborations, in this next phase, Owkin will focus on drug positioning within Sanofi’s immunology therapeutic pipeline 🎯 Autoimmune diseases, where the immune system mistakenly attacks healthy cells, come in over 80 forms including IBD, Rheumatoid Arthritis, and Lupus. Despite some being rare, collectively they affect 5% to 8% of the US population, according to The National Institutes of Health 🎯 Owkin will use its knowledge and machine learning with different types of data to find the best disease targets and identify the most responsive patient groups for specific drugs 🎯 The companies aim to help improve patient outcomes through the integration of AI and data into drug development programs ultimately enabling patients to receive the most effective therapy based on the specific molecular and cellular features driving their disease 🎯 In November 2021, Sanofi made an equity investment of $180 million and entered into a strategic alliance with Owkin to work on drug discovery and development programmes in oncology 👇Link to articles in comments below #DigitalHealth #AI 

Cytoplasmic Tyrosine Kinases (CTKs): Tragteted chronic disease therapy and use of AI-powered prediction of drug responses The Cellular Signaling Masters Fascinating research spotlight on these crucial molecular switches that control cell fate! 🧬 📊 Key Insights on CTKs: Critical Cell Regulators: Control cell growth & division Manage cell differentiation Regulate cell survival Direct immune responses Major Players in Disease: ▪️ JAK - Blood cancers & autoimmune conditions ▪️ ABL - Chronic myeloid leukemia ▪️ SYK - Rheumatoid arthritis ▪️ SRC - Multiple cancer types 🔍 Latest Research Developments (2024): Novel selective inhibitors showing promising results Dual-targeting approaches reducing resistance Advanced screening methods for better drug design AI-powered prediction of drug responses 💊 Clinical Impact: Several FDA-approved CTK inhibitors transforming cancer treatment New generation drugs showing fewer side effects Breakthrough therapies for autoimmune disorders Personalized medicine approaches based on CTK profiles 🎯 Why This Matters: Understanding CTKs is revolutionizing treatment for: Various cancer types Inflammatory diseases Autoimmune conditions Chronic disorders 🚀 Future Directions: Combination therapy strategies Enhanced specificity inhibitors Biomarker-driven patient selection Novel delivery systems #MolecularBiology #CancerResearch #DrugDiscovery #Biotechnology #MedicalScience #Research #Oncology #Immunology #PharmaceuticalScience #Innovation Interested in the latest CTK research? Let's connect and discuss how these developments are shaping precision medicine!

🌟 Big Moves in Immunology! 🌟 Johnson & Johnson has just made headlines again with a massive $1.25 billion investment! 💰 They've acquired the rights to Numab Therapeutics' revolutionary NM26, a bispecific antibody geared toward tackling atopic dermatitis and potentially other inflammatory skin conditions. 🧬🩺 This decisive move comes hot on the heels of their recent $850 million Proteologix deal, reaffirming J&J's strategic focus on advanced immunology treatments. With NM26 showing promising early data and nearing phase 2 trials, it's clear J&J is reinforcing its legacy and dedication to address critical patient needs. 💉✨ As a leader in biotech advancements, J&J's strategic investments highlight the vital importance of continuous innovation to meet unmet medical needs. It's not just about acquiring assets, but about nurturing potential life-changing therapies. Let's keep an eye on this space - J&J's commitment may just pave the way for next-gen treatments. 🚀 #Immunology #HealthcareInnovation #BispecificAntibodies

𝐀𝐂 𝐈𝐦𝐦𝐮𝐧𝐞 𝐔𝐧𝐯𝐞𝐢𝐥𝐬 𝐆𝐫𝐨𝐮𝐧𝐝𝐛𝐫𝐞𝐚𝐤𝐢𝐧𝐠 𝐦𝐨𝐫𝐀𝐃𝐂 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 𝐟𝐨𝐫 𝐍𝐞𝐮𝐫𝐨𝐝𝐞𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐯𝐞 𝐃𝐢𝐬𝐞𝐚𝐬𝐞𝐬 AC Immune SA (NASDAQ: ACIU) AC Immune unveiled a novel class of neurodegenerative disease-fighting drug candidates called morADC (Morphomer® Antibody Drug Conjugate) at AAIC 2024. Presented by Dr. Madiha Derouazi Madiha Derouazi, morADC shows significant promise: Designed for CNS applications, targeting Abeta, Tau, and a-synuclein. Enables single or dual-targeting strategies to deliver combination therapy. Demonstrates significant synergistic anti-aggregation effects. Enhances brain penetration compared to parent antibodies alone. Unlike oncology ADCs, morADC combines the brain penetrance of Morphomer small molecules with the target specificity of monoclonal antibodies to reduce pathological proteins in the CNS. Dr. Andrea Pfeifer Andrea Pfeifer, CEO, remarked: “morADC technology synergistically combines our SupraAntigen and Morphomer platforms, offering unique functionality and potentially disruptive capabilities in our industry. We are excited to develop these first-in-class therapeutic candidates to pioneer precision prevention for neurodegenerative diseases.” SupraAntigen discovers and develops active and passive immunotherapies, while the Morphomer platform identifies small molecules targeting pathological protein aggregates. The combination enhances blood-brain barrier penetration and efficacy against therapeutic targets, aiming to improve clinical outcomes for patients. #Neurodegeneration #Biopharma #Innovation #DrugDiscovery #PrecisionMedicine #ACImmune #AAIC2024 #CNS #AntibodyDrugConjugates #HealthcareInnovation

COYA 301 and Glucagon-Like Peptide-1 receptor agonists (GLP-1 RAs) are showing promise in the fight against inflammatory diseases. Their synergistic anti-inflammatory effects target various cell types, enhancing regulatory T cell function, suppressing pro-inflammatory cells, and promoting anti-inflammatory phenotypes. This multi-targeted approach addresses multiple pathways simultaneously, offering new hope in treating complex immune-based conditions like Alzheimer’s Disease. Coya Therapeutics, Inc. is at the forefront of investigating these combinations to develop innovative therapeutic strategies for severe systemic, neuro-inflammatory, autoimmune, and metabolic conditions. By expanding their pipeline with proprietary combinations, Coya aims to transform the treatment landscape by targeting multiple disease mechanisms. This breakthrough approach not only extends the GLP-1 market beyond traditional uses but also opens doors for strategic partnerships and scientific collaborations. Learn more about Coya Therapeutics' groundbreaking research and the potential of their novel therapeutic approaches: https://lnkd.in/d6THuJkQ #MedicalResearch #InnovativeTherapies #InflammatoryDiseases #HealthcareInnovation Fred Grossman D.O., FAPA Arun Swaminathan Daniel Barvin, MBA Adrian Hepner, MD, PhD Michelle Frazier, Ph.D.

Unlock the potential of your research with Central BioHub's #PBMC Samples. Our Peripheral Blood Mononuclear Cell samples, sourced ethically under stringent protocols, offer unparalleled quality and versatility for studies in #immunology, #therapy, and #diagnostics. Explore tailored solutions with up to 100 million cells, ready for immediate use! 🧪 With detailed specifications, we're empowering researchers to navigate the complexities of biospecimen selection with confidence. 🔍Explore the possibilities, advance your experiments, and accelerate scientific progress. Find PBMC Samples for Research in our Inventory: https://lnkd.in/eHc_XKAy Sample Specifications: •               Up to 100M Cells •               PBMC Cells | Pellets | Pools •               Storage Temperature: -80° to -196° C •               Diagnosis: Cancer | Autoimmune | Healthy Donor #ResearchAndDevelopment #Biobanking #Diagnostics #Onlinemarketplace #DrugDiscovery #BiomedicalResearch #ClinicalResearch #IVD #Biotechnology #Healthcare #Pharma #Biomedicine #PBMC_Samples

Lipid nanoparticles for delivering mRNA therapeutics hold immense promise for the treatment of a wide range of lung-associated diseases, researchers including CRI Fellow Dr. Zebin Xiao and 2021 William B. Coley Award recipient and 2023 Nobel Laureate in Medicine, Dr. Drew Weissman, of Penn Medicine, University of Pennsylvania Health System describe. However, the lack of effective methodologies capable of identifying the pulmonary delivery profile of chemically distinct lipid libraries poses an obstacle to the advancement of mRNA therapeutics. Discover how their newest publication demonstrates the potential for developing next-generation extra hepatic delivery platforms by employing high-throughput barcoding technology as a screening tool for identifying nanoparticles with lung tropism: https://lnkd.in/e9dYaAZs #CancerResearch #mRNA #Immunotherapy